Key result
Overexpression of MYPT2 in transgenic mice decreased the level of myosin light chain phosphorylation, leading to reduced Ca2+ sensitivity of contraction, left ventricular enlargement, and impaired cardiac function.
Why the study?
Does overexpression of MYPT2 reduce Ca2+ sensitivity and impair cardiac function in transgenic mice?
Does overexpression of MYPT2 reduce Ca2+ sensitivity and impair cardiac function in transgenic mice?
Absolute Event Rate: 29.1% vs 44.3%
p-value: p=<0.05
In vivo overexpression of MYPT2 decreases myosin light chain phosphorylation, leading to reduced calcium sensitivity, left ventricular enlargement, and impaired cardiac contractility.
No takes yet. Share an insight, caveat, or question.
MYPT2 modulation may affect cardiac performance in mice; hypothesis-generating for Ca2+ sensitivity-targeted therapies in human HF.
Mizutani et al. (2009) studied Heart Failure / Cardiac Dysfunction (n=60). Overexpression of MYPT2 (Transgenic mice) vs. Wild-type mice was evaluated on Phosphorylation of ventricular regulatory myosin light chain (MLC) (p=<0.05). Overexpression of MYPT2 in transgenic mice decreased the level of myosin light chain phosphorylation, leading to reduced Ca2+ sensitivity of contraction, left ventricular enlargement, and impaired cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: